


RSC Drug Discovery

Edited by Maria Jose Alonso and Noemi S. Csaba

Nanostructured Biomaterials for Overcoming Biological Barriers




RSC Publishing

Nanostructured Biomaterials for Overcoming Biological Barriers

Edited by

Maria Jose Alonso and Noemi S. Csaba

Nanobiofar Group, Department of Pharmaceutical Technology, School of Pharmacy, Santiago de Compostela, La Coruna, Spain
E-mail: mariaj.alonso@usc.es; noemi.csaba@usc.es



RSC Publishing

RSC Drug Discovery Series No. 22

ISBN: 978-1-84973-363-2

ISSN: 2041-3203

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2012

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

The RSC is not responsible for individual opinions expressed in this work.

Published by The Royal Society of Chemistry,
Thomas Graham House, Science Park, Milton Road,
Cambridge CB4 0WF, UK

Registered Charity Number 207890

For further information see our web site at www.rsc.org

Printed in the United Kingdom by Henry Ling Limited, at the Dorset Press,
Dorchester, DT1 1HD

Nanostructured Biomaterials for Overcoming Biological Barriers

RSC Drug Discovery Series

Editor-in-Chief

Professor David Thurston, *London School of Pharmacy, UK*

Series Editors:

Dr David Fox, *Pfizer Global Research and Development, Sandwich, UK*

Professor Salvatore Guccione, *University of Catania, Italy*

Professor Ana Martinez, *Instituto de Química Medica-CSIC, Spain*

Professor David Rotella, *Montclair State University, USA*

Advisor to the Board:

Professor Robin Ganellin, *University College London, UK*

Titles in the Series:

- 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups
- 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1
- 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2
- 4: Accounts in Drug Discovery
- 5: New Frontiers in Chemical Biology
- 6: Animal Models for Neurodegenerative Disease
- 7: Neurodegeneration
- 8: G Protein-Coupled Receptors
- 9: Pharmaceutical Process Development
- 10: Extracellular and Intracellular Signaling
- 11: New Synthetic Technologies in Medicinal Chemistry
- 12: New Horizons in Predictive Toxicology
- 13: Drug Design Strategies: Quantitative Approaches
- 14: Neglected Diseases and Drug Discovery
- 15: Biomedical Imaging
- 16: Pharmaceutical Salts and Cocrystals
- 17: Polyamine Drug Discovery
- 18: Proteinases as Drug Targets
- 19: Kinase Drug Discovery
- 20: Drug Design Strategies: Computational Techniques and Applications
- 21: Designing Multi-Target Drugs
- 22: Nanostructured Biomaterials for Overcoming Biological Barriers

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247, Email: books@rsc.org

Visit our website at <http://www.rsc.org/Shop/Books/>

Preface

The book *Nanostructured Biomaterials for Overcoming Biological Barriers* provides a terrific summary of how nanostructures can be helpful in the biomedical area. It starts with a historical perspective and then goes over how nanostructures can be used to overcome different barriers in the body. Such barriers include the intestinal barrier, the nasal barrier, the ocular barrier, the pulmonary barrier, the skin barrier and finally the blood brain barrier. In each case the book is very well organized with chapters in each section going over physiological considerations and mechanistic issues followed by various formulation strategies for delivering specific types of molecules. For example, in the section for nanostructures for overcoming the intestinal barrier, oral vaccines are considered and the same is true for the section on nasal barriers. In the sections for the ocular, pulmonary, skin and blood-brain barriers; drugs, including large molecular weight drugs, are primarily discussed.

The book continues by going over how nanostructures can overcome biological barriers related to parenteral drug delivery. Here the idea of using lipid nanocapsules for parenteral drug delivery is discussed as well as how one can overcome biological barriers with parenteral nanomedicines. Finally parenteral drug delivery using polymers is evaluated.

The next chapters go over biological barriers to tissue engineering and specifically discuss physiological and mechanistic issues as well as drug delivery related to this field. Next, regulatory issues such as nanotoxicology are reviewed. This is an important area that scientists want to understand more about for the practical use of nanomedicines. Finally, a clinically relevant case study by Bioalliance Pharma is presented and the book is tied together with thoughtful closing remarks.

Overall, the book provides a very good understanding of the biological barriers and discusses the most innovative current approaches to overcome these barriers through the use of nanotechnologies and biomaterials.

Robert S. Langer
Department of Chemical Engineering,
Massachusetts Institute of Technology,
Cambridge, USA

Contents

Section 1 Historical View

Chapter 1	Historical View of the Design and Development of Nanocarriers for Overcoming Biological Barriers	3
	<i>María José Alonso and Patrick Couvreur</i>	
1.1	Introduction	3
1.2	The Barriers Being Confronted Using Nanocarriers	6
1.3	The Key Milestones in the History of Nanocarriers and Drug Delivery	8
1.3.1	Milestone: The Concept of Controlled Drug Delivery	9
1.3.2	Milestone: The Discovery of Liposomes	9
1.3.3	Milestone: The Origin of PEGnology and Polymer Therapeutics	11
1.3.4	Milestone: The origin of nanoparticles	13
1.4	Current State of the Art in Nanocarriers Development	19
1.5	The Therapeutic Expectations for the Current and Future Nanocarriers	24
1.5.1	Cancer	25
1.5.2	Cardiovascular Diseases	25
1.5.3	CNS Diseases	25
1.5.4	Infectious Diseases	26
1.6	Conclusions	28
	Acknowledgements	28
	References	28

Section 2 Nanostructures Overcoming the Intestinal Barrier

Chapter 2.1	Nanostructures Overcoming the Intestinal Barrier: Physiological Considerations and Mechanistic Issues	39
	<i>Sam Maher, Katie B. Ryan, Tauseef Ahmad, Caitriona M. O'Driscoll and David J. Brayden</i>	
2.1.1	Oral peptide and protein delivery challenges	39
2.1.2	Physicochemical and physiological barriers to drug absorption	43
2.1.3	Nanoparticle carriers as a potential solution for oral peptide delivery	45
2.1.4	Dissecting the NP uptake pathways in the intestine	49
2.1.5	Examples of NPs for oral peptide delivery	51
2.1.6	Overcoming the Intestinal Barrier with Novel polymeric NP Constructs	55
2.1.7	Conclusions	57
	Acknowledgements	57
	References	58
 Chapter 2.2	 Nanostructures Overcoming the Intestinal Barrier: Drug Delivery Strategies	 63
	<i>Katie B. Ryan, Sam Maher, David J. Brayden and Caitriona M. O'Driscoll</i>	
2.2.1	Introduction	63
2.2.2	Nanosystems – Materials and Formulation	65
2.2.2.1	Polymeric Approaches	66
2.2.2.2	Lipid Systems	74
2.2.3	Surface Modification and Targeting	77
2.2.3.1	Targeting Ligands	77
2.2.4	Novel Technologies for Nucleic Acid Delivery	78
2.2.5	Intestinal Site-Specific Delivery Using Nanosystems	79
2.2.6	Conclusions	82
	References	83
 Chapter 2.3	 Nanostructures For Oral Vaccine Delivery	 91
	<i>Carlos Gamazo and Juan M. Irache</i>	
2.3.1	Introduction	91
2.3.2	Organization of the Mucosal Immune System	93
2.3.2.1	Common Mucosal Immune System	93

2.3.2.2	Tolerance	94
2.3.2.3	PRR Recognition	94
2.3.3	Anatomy of GALT and Fate of the Orally Administered Antigens	96
2.3.3.1	Transcytosis through M Cells	98
2.3.3.2	Via Dendrites from Dendritic Cells	99
2.3.3.3	Via Epithelium Damage	100
2.3.4	Mucosal Vaccine Adjuvants	100
2.3.4.1	Factors Influencing the Efficacy of Nanoparticles as Oral Adjuvants	101
2.3.5	Efficacy of Nanoparticles as Mucosal Adjuvants for Vaccination	104
2.3.6	Conclusions	108
	References	109

Section 3 Nanocarriers Overcoming the Nasal Barriers

Chapter 3.1	Nanocarriers Overcoming the Nasal Barriers: Physiological Considerations and Mechanistic Issues	117
	<i>António J. Almeida and Helena F. Florindo</i>	
3.1.1	Introduction	117
3.1.2	The Nasal Route of Administration	118
3.1.3	Physiological Barriers Associated to the Nasal Cavity	119
3.1.4	Mechanisms of Particle Uptake and Translocation at the Nasal Cavity	121
3.1.4.1	Transport via the M-cells of NALT	124
3.1.4.2	Transcellular Transport via the Epithelial Cells	124
3.1.4.3	Paracellular Transport Between Epithelial Cells	124
3.1.4.4	Particle Uptake and Translocation to the CNS	126
3.1.5	Conclusions	128
	References	129
Chapter 3.2	Nanostructures Overcoming the Nasal Barrier: Protein and Peptide Delivery Strategies	133
	<i>Cecilia Prego and Francisco M. Goycoolea</i>	
3.2.1	Introduction	133

3.2.2	Nasal Bioavailability of Therapeutic Peptides and Proteins	134
3.2.3	Nanocarriers for Intranasal Delivery of Peptide/Proteins	138
3.2.3.1	Polymer Nanoparticles	139
3.2.3.2	Lipidic Nanosystems	148
3.2.4	Conclusions	150
	References	151
Chapter 3.3	Nanostructures for Nasal Vaccine Delivery	156
	<i>Bram Slütter and Wim Jiskoot</i>	
3.3.1	Introduction	156
3.3.2	The Nasal Cavity as Application Site for Vaccination	157
3.3.3	Challenge in Nasal Vaccination	159
3.3.3.1	Nasal Subunit Vaccine Design is Tough	159
3.3.3.2	Mucus	159
3.3.3.3	Epithelium	160
3.3.3.4	Nasal Tolerance	160
3.3.4	Nasal Vaccine Design	161
3.3.4.1	Penetrating Mucus and Prolonging Nasal Residence Time	161
3.3.4.2	Crossing Epithelium and M-cell Targeting	162
3.3.4.3	Overcoming Nasal Tolerance and Use of Adjuvants	165
3.3.4.4	Further Clinical and Formulation Challenges	166
3.3.5	Conclusion	167
	References	167

Section 4 Nanostructures Overcoming the Ocular Barrier

Chapter 4.1	Nanostructures Overcoming the Ocular Barrier: Physiological Considerations and Mechanistic Issues	173
	<i>Clive G. Wilson and Lay Ean Tan</i>	
4.1.1	Introduction	173
4.1.2	Topical Ocular Barriers	174
4.1.2.1	Corneal Barriers	175
4.1.2.2	The Scleral and Conjunctival Barriers	177
4.1.3	Barriers of the Inner Globe	178
4.1.3.1	Aqueous Humour	178
4.1.3.2	Uveal Tract	180

4.1.3.3	The Lens	180
4.1.3.4	Vitreous humour	181
4.1.3.5	Posterior Vitreous Detachment (PVD)	183
4.1.3.6	The Choroid and Retinal Blood Supply	183
4.1.3.7	The Retina	184
4.1.3.8	Retinal Pigment Epithelium	184
4.1.3.9	The Retinal Vascular Barrier	186
4.1.4	Conclusion	186
	References	186

Chapter 4.2 Nanostructures Overcoming the Ocular Barrier: Drug Delivery Strategies **190**
Arto Urtti

4.2.1	Introduction	190
4.2.2	Topical Ocular Drug Delivery	192
4.2.2.1	Pharmacokinetics of Topical Ocular Drugs	194
4.2.2.2	Delivery Approaches	195
4.2.3	Intravitreal Drug Delivery	197
4.2.3.1	Pharmacokinetics of Intravitreal Drugs	198
4.2.3.2	Delivery Approaches	199
4.2.4	Periocular Drug Delivery	199
4.2.4.1	Pharmacokinetics of Periocular Drug Administration	200
4.2.4.2	Delivery Approaches	201
4.2.5	Other Routes of Administration	201
4.2.5.1	Systemic Administration	201
4.2.5.2	Sub-retinal Administration	202
4.2.6	Conclusion	202
	References	202

Chapter 4.3 Ocular Drug Delivery from Nanostructured Contact Lenses **205**
Carmen Alvarez-Lorenzo and Angel Concheiro

4.3.1	Contact Lens-Drug Combination Products	205
4.3.2	Drug-eluting Conventional Contact Lenses	206
4.3.2.1	Key Factors for Drug Loading Yield and Release Rate	209
4.3.3	Nanostructured Contact Lenses for Drug Delivery	211
4.3.3.1	Colloidal Nanocarriers	213
4.3.3.2	Pendant Cyclodextrins	217
4.3.3.3	Imprinted Pockets	218
4.3.4	Conclusions	231
	References	231

Section 5 Nanostructures for Overcoming the Pulmonary Barriers

Chapter 5.1 Nanostructures for Overcoming the Pulmonary Barriers: Physiological Considerations and Mechanistic Issues	239
<i>Julian Kirch, Christian A. Ruge, Craig Schneider, Justin Hanes and Claus-Michael Lehr</i>	
5.1.1 The Lungs as a Route for Drug Delivery	240
5.1.1.1 Introduction: Why is the Lung a Good Place to Deliver Drugs?	240
5.1.1.2 Physiological Features Influencing Lung Deposition	240
5.1.1.3 New approaches	242
5.1.2 What Happens After Landing? – A Shift of Paradigm in Pulmonary Drug Delivery	244
5.1.3 Cellular Barriers	245
5.1.3.1 Epithelial Barriers	245
5.1.3.2 Macrophage Clearance	248
5.1.4 Non-Cellular Barriers – The Lung Surface Lining	251
5.1.4.1 Mucus and Mucociliary Clearance	252
5.1.4.2 Pulmonary Surfactant	259
5.1.5 Conclusion	262
References	263
 Chapter 5.2 Nanostructures for Overcoming the Pulmonary Barrier: Drug Delivery Strategies	 273
<i>Paolo Colombo, Fabio Sonvico and Francesca Buttini</i>	
5.2.1 Pulmonary Drug Delivery Applications	273
5.2.2 Nebulizers	275
5.2.3 Pressurized Metered Dose Inhalers	283
5.2.4 Dry powder Inhalers	285
5.2.5 Conclusions	297
References	297

Section 6 Nanostructures Overcoming the Skin Barrier

Chapter 6.1 Physiological and Mechanistic Issues of the Skin Barrier	303
<i>M. J. Alvarez-Figueroa and Pablo M. González</i>	
6.1.1 The Skin	303

6.1.2	Transdermal Drug Delivery	304
6.1.3	Routes for Transdermal Absorption	304
6.1.4	Factors Determining Transdermal Permeability	305
6.1.4.1	Physicochemical Properties of Drugs	306
6.1.4.2	Physicochemical Properties of the Delivery System	306
6.1.4.3	Physiological and Physiopathological Conditions of the Skin	306
6.1.5	Strategies for Transdermal Drug Delivery	307
6.1.5.1	Permeation Enhancers	308
6.1.5.2	Microemulsions	308
6.1.5.3	Liposomes	309
6.1.5.4	Iontophoresis	310
6.1.5.5	Sonophoresis	311
6.1.5.6	Electroporation	311
6.1.5.7	Microneedles	311

Chapter 6.2 Nanostructures Overcoming the Skin Barrier: Drug Delivery Strategies **316**

Nathalie Schleich and Véronique Prétat

6.2.1	Topical and Transdermal Drug Delivery	316
6.2.2	Skin Barrier and Penetration Pathways of Drug Loaded Nanoparticles	317
6.2.3	Lipid-based Nanoparticles for Topical and Transdermal Drug Delivery	319
6.2.3.1	Liposomes	319
6.2.3.2	Niosomes	321
6.2.3.3	Deformable Vesicles	321
6.2.3.4	Solid Lipid Particles	322
6.2.4	Polymeric Nanoparticles for Topical and Transdermal Drug Delivery	322
6.2.5	Lipid- and Polymer-based Nanocarriers in Dermatology	323
6.2.6	Conclusions	324
	References	324

Section 7 Nanostructures Overcoming the Blood-Brain Barrier

Chapter 7.1 Nanostructures Overcoming the Blood-Brain Barrier: Physiological Considerations and Mechanistic Issues **329**

Aikaterini Lalatsa, Andreas G. Schätzlein and Ijeoma F. Uchegbu

7.1.1	The Blood-Brain Barrier	329
7.1.2	Transcellular (Lipophilic) Diffusion	334
7.1.2.1	Lipophilicity	334
7.1.2.2	Plasma Protein Binding	334
7.1.2.3	Brain Tissue Binding	335
7.1.2.4	Efflux Transporters-ATP Binding Cassette Transporters	335
7.1.2.5	Exploiting Transcellular Pathways	335
7.1.3	Carrier Mediated Transport	340
7.1.3.1	Exploiting Carrier Mediated Transcytosis	340
7.1.4	Receptor Mediated Transcytosis	344
7.1.4.1	Exploiting Receptor Mediated Transcytosis	345
7.1.5	Adsorptive Mediated Transcytosis	353
7.1.5.1	Exploiting Adsorptive Mediated Transcytosis	354
7.1.6	Conclusions	355
	References	356
Chapter 7.2	Drug Delivery Strategies: BBB–Shuttles	364
	<i>R. Prades, M. Teixidó and E. Giralt</i>	
7.2.1	Introduction	364
7.2.2	Transports through the BBB	365
7.2.3	Drug delivery to the brain	366
7.2.3.1	Invasive strategies	366
7.2.3.2	Pseudo-invasive strategies	367
7.2.3.3	Non-invasive drug delivery to the brain	368
7.2.4	Conclusions and Perspectives	381
	References	383
Chapter 7.3	Drug Delivery Strategies: Nanostructures for Improved Brain Delivery	392
	<i>Maria de la Fuente, Maria V. Lozano, Ijeoma F. Uchegbu and Andreas G. Schätzlein</i>	
7.3.1	Engineering of Nanostructures for Brain Delivery	392
7.3.2	BBB Mechanisms and Methods	394
7.3.3	Enhanced CNS Activity Through Improved Systemic Bioavailability	401
7.3.4	Bypassing the Blood-Brain Barrier	402
7.3.4.1	Invasive Administration	402
7.3.4.2	Nose-to-brain Transport	407
7.3.5	Crossing the Blood-Brain Barrier	409

7.3.5.1	Non-specific Blood-Brain barrier Interaction	412
7.3.5.2	Ligand/Receptor-mediated BBB Interaction	415
7.3.6	Conclusions	421
	References	423

Section 8 Overcoming Biological Barriers with Parenteral Nanomedicines

Chapter 8.1	Overcoming Biological Barriers with Parenteral Nanomedicines: Physiological and Mechanistic Issues	435
	<i>Lin Zhu, Sara Movassaghian and Vladimir P. Torchilin</i>	
8.1.1	Introduction	435
8.1.2	Biological Barriers for Parenteral Nanomedicines	436
8.1.2.1	Biological Membranes and Matrices	436
8.1.2.2	The Immune System	440
8.1.2.3	Pharmacokinetic (PK) Barriers	440
8.1.3	Delivery Strategies and Applications of Parenteral Nanomedicines	441
8.1.3.1	Blood Circulation Time and Passive Targeting	442
8.1.3.2	Surface Modification with Targeting Moieties	444
8.1.3.3	Stimuli-sensitive Targeting	446
8.1.3.4	Intracellular Delivery and Endosomal Escape	448
8.1.3.5	Multifunctional Nanomedicines	451
8.1.4	Conclusion	451
	References	452
Chapter 8.2	Drug Delivery Strategies: Polymer Therapeutics	456
	<i>Richard M. England, Inmaculada Conejos-Sánchez and María J. Vicent</i>	
8.2.1	Introduction	456
8.2.1.1	Polymer Therapeutics. Concept and Current Status	457
8.2.2	Parenteral Drug Delivery of Polymer Therapeutics	458
8.2.2.1	Intravenous	458

8.2.2.2	Subcutaneous and Intramuscular Delivery	474
8.2.2.3	Intratumoural	474
8.2.2.4	Intraperitoneal	475
8.2.3	Conclusions and Future Perspectives	475
	Acknowledgements	476
	References	476
Chapter 8.3	Drug Delivery Strategies: Lipid Nanocapsules	483
	<i>G. Bastiat, S. Hirsjärvi and J. P. Benoit</i>	
8.3.1	Introduction	483
8.3.2	Easy and Safe Method for the Formulation of Lipid Nanocapsules	484
8.3.3	Lipid Nanocapsules and Blood Circulation	486
8.3.3.1	Unmodified LNCs and Blood Circulation	486
8.3.3.2	Modified LNCs and Blood Circulation	487
8.3.4	Lipid Nanocapsules and Cellular Uptake	488
8.3.4.1	P-glycoprotein Inhibition	488
8.3.4.2	Cellular Trafficking	489
8.3.5	Lipid Nanocapsules and Passive Targeting vs. Active Targeting.	490
8.3.5.1	Passive Targeting and the EPR Effect	490
8.3.5.2	Active Targeting and Crossing the Blood-Brain Barrier	492
8.3.6	Lipid Nanocapsules and Cancer Therapy: an Orthotopic Hepatocarcinoma Model	492
8.3.7	Lipid Nanocapsules and Inner Ear Diseases	494
8.3.8	Conclusions	495
	References	496
Section 9 Drug Delivery in Tissue Engineering		
Chapter 9.1	Drug Delivery in Tissue Engineering: General Concepts	501
	<i>T. Simón-Yarza, E. Garbayo, E. Tamayo, F. Prósper and M. J. Blanco-Prieto</i>	
9.1.1	Tissue Engineering: Definition and Objectives	501
9.1.1.1	Cell Sources in Tissue Engineering	503
9.1.1.2	Bioactive Molecules in Tissue Engineering	504
9.1.1.3	Scaffolds in Tissue Engineering	505